Study record
Identification of navitoclax as a senolytic targeting the Bcl-2 family (Zhu et al., 2016)
In vitro / ex vivo
○ Evidence tier 7 — In vitro / ex vivo
Record verify: verified against primary source
| Design | Preclinical mechanism (cell culture) |
| DOI | 10.1111/acel.12445 |
| Citation status | doi verified via Crossref 2026-07-12 (Aging Cell 2016;15(3):428-435, Zhu et al.) |
Identifiers: DOI verified; PMID not reported; trial registry id not applicable to this study type. Record-level verification and identifier-level status are separate: a record can be fully verified against its primary publication while an identifier that cannot apply to the study type — a trial registry ID for an animal study, for instance — is marked not applicable. No identifier is fabricated, and none is left in a “pending” state.
Five-qualifier claim
| Species / population | Cultured senescent human and mouse cells. |
| Exposure, route, schedule | ABT-263 (navitoclax) in vitro. |
| Comparator / duration | Non-senescent vs senescent cells. |
| Endpoint / numeric result | Navitoclax selectively killed senescent cells by inhibiting Bcl-2/Bcl-xL, establishing a targeted senolytic mechanism. |
| What it did NOT establish | In vitro / mechanism; no human senolytic outcome. |